| FT516 and IL2 With Enoblituzumab for Ovarian Cancer (NCT04630769) | Masonic Cancer Center, University of Minnesota | 2021-04-02 |
| Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer (NCT01402271) | European Organisation for Research and Treatment of Cancer - EORTC | 2012-07-01 |
| Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer (NCT01656044) | Wake Forest University Health Sciences | 2012-06-01 |
| S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00872989) | SWOG Cancer Research Network | 2010-03-01 |
| Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin (NCT00993616) | National Cancer Institute (NCI) | 2009-12-01 |
| Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer (NCT00903396) | Alliance for Clinical Trials in Oncology | 2009-09-01 |
| Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT01100372) | Medical University Innsbruck | 2009-07-01 |
| Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix (NCT01580410) | Wake Forest University Health Sciences | 2009-05-01 |
| Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (NCT00569673) | Gynecologic Oncology Group | 2008-03-01 |
| Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer (NCT00769405) | UNICANCER | 2008-02-01 |
| AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00574951) | Gynecologic Oncology Group | 2007-12-01 |
| Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) (NCT00562640) | Memorial Sloan Kettering Cancer Center | 2007-10-16 |
| Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission (NCT00522301) | Memorial Sloan Kettering Cancer Center | 2007-07-01 |
| Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer (NCT00766142) | Institut Bergonié | 2007-05-01 |
| Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00459290) | Gynecologic Oncology Group | 2007-05-01 |
| Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer (NCT00458809) | Wake Forest University Health Sciences | 2007-03-01 |
| Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00429793) | National Cancer Institute (NCI) | 2007-02-01 |
| Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00407758) | Gynecologic Oncology Group | 2006-11-01 |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma (NCT00398138) | Memorial Sloan Kettering Cancer Center | 2006-10-01 |
| Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT00303888) | Yale University | 2006-05-01 |
| Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT00373217) | Craig L Slingluff, Jr | 2006-04-13 |
| Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer (NCT00334893) | National Cancer Institute (NCI) | 2006-04-01 |
| Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00897039) | Southeastern Gynecologic Oncology | 2006-03-01 |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer (NCT00601406) | The Christie NHS Foundation Trust | 2006-03-01 |
| Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer (NCT00132067) | National Cancer Institute (NCI) | 2005-10-01 |
| Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer (NCT00263822) | European Organisation for Research and Treatment of Cancer - EORTC | 2005-09-01 |
| 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer (NCT00081276) | National Cancer Institute (NCI) | 2005-07-01 |
| Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer (NCT00113373) | National Cancer Institute (NCI) | 2005-05-01 |
| Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT00126542) | National Cancer Institute (NCI) | 2005-04-01 |
| EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer (NCT00107445) | National Cancer Institute (NCI) | 2005-02-01 |
| Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (NCT00138242) | Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center | 2004-12-01 |
| Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer (NCT00091195) | National Cancer Institute (NCI) | 2004-09-01 |
| Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00091377) | MEI Pharma, Inc. | 2004-08-01 |
| Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00087087) | Gynecologic Oncology Group | 2004-07-01 |
| Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00086892) | Gynecologic Oncology Group | 2004-06-01 |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00079430) | National Cancer Institute (NCI) | 2004-06-01 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (NCT00087191) | National Cancer Institute (NCI) | 2004-05-01 |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) (NCT00085358) | National Cancer Institute (NCI) | 2004-05-01 |
| Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00408590) | Mayo Clinic | 2004-04-19 |
| Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer (NCT00084448) | Gynecologic Oncology Group | 2004-04-01 |
| Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00098878) | NHS Greater Glasgow and Clyde | 2004-03-01 |
| UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00072267) | University Health Network, Toronto | 2004-01-01 |
| Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT00075712) | Royal College of Obstetricians and Gynecologists | 2003-09-01 |
| Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors (NCT00066651) | National Cancer Institute (NCI) | 2003-07-01 |
| Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00066729) | Ludwig Institute for Cancer Research | 2003-06-23 |
| Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer (NCT00053365) | National Cancer Institute (NCI) | 2003-06-01 |
| S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00053833) | SWOG Cancer Research Network | 2003-04-01 |
| Gefitinib in Treating Patients With Cervical Cancer (NCT00049556) | National Cancer Institute (NCI) | 2002-10-01 |
| Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy (NCT00025155) | National Cancer Institute (NCI) | 2002-07-01 |
| Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer (NCT00041041) | National Cancer Institute (NCI) | 2002-06-01 |
| UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT00045175) | University Health Network, Toronto | 2002-06-01 |
| Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor (NCT00039585) | National Cancer Institute (NCI) | 2002-05-01 |
| Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00055614) | Beth Israel Deaconess Medical Center | 2002-05-01 |
| Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00022659) | National Cancer Institute (NCI) | 2002-04-01 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer (NCT00036751) | National Cancer Institute (NCI) | 2002-04-01 |
| Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00023712) | National Cancer Institute (NCI) | 2001-11-05 |
| Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (NCT00028912) | Memorial Sloan Kettering Cancer Center | 2001-11-01 |
| EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer (NCT00028782) | National Cancer Institute (NCI) | 2001-10-01 |
| Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00023699) | Gynecologic Oncology Group | 2001-08-01 |
| Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer (NCT00031954) | AGO Study Group | 2001-08-01 |
| Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00023907) | Gynecologic Oncology Group | 2001-07-01 |
| Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer (NCT00016289) | National Cancer Institute (NCI) | 2001-07-01 |
| Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer (NCT00020696) | Gynecologic Oncology Group | 2001-06-01 |
| TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00022347) | Memorial Sloan Kettering Cancer Center | 2001-05-01 |
| ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00014690) | AstraZeneca | 2001-03-01 |
| Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00021034) | Memorial Sloan Kettering Cancer Center | 2001-03-01 |
| Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer (NCT00006812) | Gynecologic Oncology Group | 2001-03-01 |
| CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT00017017) | Memorial Sloan Kettering Cancer Center | 2001-02-01 |
| Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy (NCT00006028) | Gynecologic Oncology Group | 2001-01-01 |
| Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer (NCT00017303) | Cytran | 2001-01-01 |
| Immunotoxin Therapy in Treating Patients With Advanced Cancer (NCT00006981) | National Cancer Institute (NCI) | 2000-12-01 |
| Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00006942) | National Cancer Institute (NCI) | 2000-10-01 |
| Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum (NCT00012090) | Memorial Sloan Kettering Cancer Center | 2000-09-01 |
| Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer (NCT00005025) | John Stoddard Cancer Center at Iowa Methodist Medical Center | 2000-06-01 |
| Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer (NCT00045461) | Ludwig-Maximilians - University of Munich | 2000-06-01 |
| Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer (NCT00005046) | Gynecologic Oncology Group | 2000-04-01 |
| Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer (NCT00005029) | Gynecologic Oncology Group | 2000-02-01 |
| Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT00006041) | Memorial Sloan Kettering Cancer Center | 2000-02-01 |
| Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00003967) | Gynecologic Oncology Group | 1999-09-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |
| Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer (NCT00004934) | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 1999-08-01 |
| Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT00004060) | Daiichi Sankyo | 1999-07-01 |
| Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors (NCT00004082) | Beth Israel Deaconess Medical Center | 1999-07-01 |
| Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer (NCT00005944) | UNICANCER | 1999-07-01 |
| SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) (NCT00002960) | Merck Sharp & Dohme LLC | 1999-06-01 |
| ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment (NCT00005645) | Genzyme, a Sanofi Company | 1999-05-01 |
| Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00003385) | Gynecologic Oncology Group | 1999-03-01 |
| Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer (NCT00003880) | Merck Sharp & Dohme LLC | 1999-02-01 |
| Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum (NCT00003523) | Gynecologic Oncology Group | 1999-01-01 |
| Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00004012) | Memorial Sloan Kettering Cancer Center | 1998-12-01 |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy (NCT00004115) | Jonsson Comprehensive Cancer Center | 1998-12-01 |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer (NCT00004064) | AltaRex | 1998-11-01 |
| Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer (NCT00003670) | Eli Lilly and Company | 1998-10-01 |
| Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer (NCT00003998) | University of Glasgow | 1998-10-01 |
| Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer (NCT00003636) | European Organisation for Research and Treatment of Cancer - EORTC | 1998-09-01 |
| Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer (NCT00003378) | Gynecologic Oncology Group | 1998-08-01 |
| Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer (NCT00004037) | Gynecologic Oncology Group | 1998-06-01 |
| Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer (NCT00003382) | Gynecologic Oncology Group | 1998-05-01 |
| Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00003560) | Herbert Irving Comprehensive Cancer Center | 1998-05-01 |
| Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00019461) | National Cancer Institute (NCI) | 1998-04-01 |